Last updated: May 25, 2026
CEFAZOLIN SODIUM is an injectable first-generation cephalosporin used for surgical prophylaxis and bacterial infections. Supplier access is dominated by a small set of sterile injectable manufacturers plus distributor and repackager networks. Supply risk is concentrated in sterile manufacturing capacity, generic product lineups, and regulatory status (FDA approvals and labeling history), not the active ingredient itself.
Who supplies cefazolin sodium in the US market?
Primary supply channels: manufacturers vs. distributors
Most US “suppliers” for cefazolin sodium are either:
- ANDA/NDA sterile injectable manufacturers producing cefazolin sodium injection under FDA-approved labeling
- Wholesalers and hospital group purchasing platforms distributing finished dosage forms
- Contract sterile fill-finish and CMOs supporting manufacturers (often not visible to end-users)
- Repackagers for certain package sizes or label configurations (when permitted)
What this means for sourcing
Buying cefazolin sodium usually maps to one of these procurement tracks:
- Direct through a manufacturer or authorized distributor
- Through GPO pricing channels for hospitals and health systems
- Through emergency supply or allocated product during shortages
Which companies manufacture cefazolin sodium injection (sterile powder/lyophilized and reconstituted formats)?
How to identify manufacturers
US market listings commonly track the NDC holder (labeler) and the FDA-approved application holder behind each NDC. For cefazolin sodium, manufacturing visibility is best obtained from:
- FDA “Drugs@FDA” approval records (application holders)
- The Orange Book entry for the relevant application (for products with listed patents)
- NDC directory mappings (labeler and application references)
Typical product characteristics
Cefazolin sodium is supplied as a sterile injection (commonly as a dry powder for reconstitution with diluent). Supplier product portfolios usually differ by:
- Strength (eg, 1 g and 2 g vials are common)
- Packaging and NDC
- Labeling format (reconstitution instructions and indications)
- Compatibility details for administration routes
What is the Orange Book status of cefazolin sodium products?
Do cefazolin sodium generics have listed patents?
Older small-molecule antibiotics like cefazolin sodium often have limited remaining patent estates in the US, but patent listings vary by specific ANDA application and by the time of listing. For sourcing and litigation risk, what matters is:
- Whether a given ANDA still has listed patents in the Orange Book
- Whether patents are tied to formulation, manufacturing method, or process
- Whether the product is covered by any exclusivity tied to application amendments or supplements (less common than for newer drugs)
Featured snippet answer
Orange Book coverage for cefazolin sodium is application-specific and should be verified by NDC and ANDA holder rather than assuming uniform patent status across all brands.
How does sterile injectable manufacturing capacity affect cefazolin sodium supply?
Supply constraints that matter
Cefazolin sodium is not a complex biologic, but supply bottlenecks are real because the finished product is a sterile injectable. The constraints typically include:
- Sterile aseptic processing slots or sterile fill-finish capacity
- Compliance history under FDA cGMP
- Availability of validated containers/closures and lyophilized manufacturing workflows
- Raw material supply continuity (cefazolin sodium API availability and qualified grades)
Operational risk drivers
When shortages occur, they are usually tied to:
- Plant disruptions (inspection findings, remediation, equipment failure)
- Batch rejection rates tied to sterility assurance, endotoxin specs, or moisture control in dry products
- Delays in release testing and distribution
What generic entry risks exist for cefazolin sodium?
Are there credible Paragraph IV triggers?
For older antibiotics, Paragraph IV litigation patterns are less frequent than for on-patent specialty drugs. The key risk lens becomes:
- Whether any listed Orange Book patents exist for a specific ANDA holder
- Whether any remaining exclusivity or citations affect new approval timing
Practical risk for buyers
For procurement, the main risk is less “market entry delay” and more “which suppliers can produce and ship without interruption.” Patent estate risk is secondary unless there is active litigation around a specific product.
Which suppliers have the strongest distribution footprint?
Distribution footprint is product-dependent
In practice, “top suppliers” for cefazolin sodium are those with:
- Broad NDC portfolios across multiple vial strengths
- Stable FDA supply continuity
- Relationships with large distributors and group purchasing organizations
How to score supplier strength
A usable supplier scoring model for cefazolin sodium centers on:
- Historical shipment consistency (backorder frequency)
- Coverage across the NDC set (more than one labeler reduces dependency)
- Ability to meet hospital inventory cadence (case pack size and lead times)
- Track record of FDA compliance and supply notifications
What are the main constraints for contract manufacturing of cefazolin sodium?
CMC barriers that limit new suppliers
Even with API availability, a new entrant must handle:
- Sterile manufacturing validation
- Stability and shelf-life qualification for the specific container closure
- Reconstitution performance and labeling claims
- Quality systems for batch release and sterility testing
Why this matters for sourcing
It limits the number of qualifying finished-dose suppliers, which concentrates supply risk.
How should purchasers evaluate cefazolin sodium suppliers during shortages?
Supplier due diligence checklist
For each candidate supplier (or distributor carrying their NDC), evaluate:
- FDA approved status of the specific NDC
- Sterile manufacturing site and compliance history
- Product strength alignment with your formulary (1 g vs 2 g or other)
- Packaging and storage conditions
- Lead time reliability under shortage conditions
- Allocation history (whether they frequently restrict order volumes)
Procurement strategy
Use multi-sourcing across:
- At least two NDC labelers with distinct manufacturing origins
- Multiple vial strengths if your clinical protocols allow interchangeability
- Backup distributors with independent inventory
Key Takeaways
- Cefazolin sodium sourcing in the US is primarily a function of FDA-approved sterile injectable manufacturers plus wholesaler/GPO distribution.
- Supply risk is concentrated in sterile fill-finish capacity, cGMP compliance, batch release performance, and release testing timelines, not in active ingredient patent barriers.
- “Top suppliers” should be verified by NDC and application holder because cefazolin sodium’s market lineup is fragmented by product packaging and labelers.
- For shortage resilience, purchasers should rely on multi-NDC and multi-manufacturer sourcing with verified FDA status per strength and vial configuration.
FAQs
1) How do I confirm which company is the NDC labeler for cefazolin sodium?
Use the NDC directory to map the NDC to the labeler/manufacturer and then cross-check with Drugs@FDA for the application holder.
2) Are cefazolin sodium vials interchangeable across suppliers?
Interchangeability depends on matching strength, dosage form, and approved labeling. Procurement should validate NDC-to-NDC equivalence and storage/reconstitution requirements.
3) Do cefazolin sodium products face drug shortages often?
Shortages can occur due to sterile manufacturing and quality release bottlenecks. Track FDA shortage notifications and historical backorder patterns by NDC.
4) Are there any active patents or exclusivity impacting cefazolin sodium generic supply?
Patent and exclusivity status is application-specific and should be checked in the Orange Book per NDC/ANDA, not assumed across the class.
5) What is the biggest operational reason cefazolin sodium supply can tighten?
Sterile injectable manufacturing constraints, including batch release testing capacity and sterile process performance.
References
- FDA. Drugs@FDA. https://www.accessdata.fda.gov/scripts/cder/daf/
- FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/
- FDA. NDC Directory. https://www.fda.gov/drugs/drug-approvals-and-databases/national-drug-code-directory
